New cancer drug enters first human safety tests
NCT ID NCT07086768
Summary
This is an early safety study for a new drug called BSI-082, designed for adults with advanced solid tumors that have spread or stopped responding to standard treatments. The study has two parts: first testing BSI-082 alone at increasing doses, then testing it combined with another cancer drug. The main goal is to find safe dose levels and understand side effects, not to cure the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.